News

The lawsuit covers some or all of US patent Nos. 5,061,703; 8,039,009; 8,168,209; 8,173,708; 8,283,379; 8,329,752; 8,362,085; and 8,598,233. Forest licenses the ‘703 patent, which expires in April

After the consolidation, the new division will be called the R&D division. The purposes of the reorganization are to advance Kyowa Hakko Kirin’s ‘category-based strategy’ and enhance the

HETLIOZ is claimed to be the first FDA approved medication for Non-24, a chronic, circadian rhythm disorder resulting from the misalignment of the endogenous master body clock to

Around 300 patients with glaucoma or ocular hypertension will be enrolled in the 28-day trial, who will compare two concentrations of PG324 to latanoprost and to AR-13324, all

The FDA has issued an action date of 15 September 2014 under the Prescription Drug User Fee Act (PDUFA). Budesonide is a high potency corticosteroid developed to reduce

The trial was carried out under a US Food and Drug Administration (FDA) IND (Investigational New Drug) protocol, and it met all primary and secondary endpoints. A total

The agreement is for both Gelclair, an FDA-approved bioadherent oral rinse gel for treating the painful symptoms of oral mucositis (OM), and Soltamox (tamoxifen citrate) oral liquid solution,

The Phase II clinical trial of ‘tivozanib’ is intended for patients with locally recurrent or metastatic triple negative breast cancer (TNBC). AVEO, which was developing tivozanib in collaboration

Pursuant to the terms of the agreement, YODA will serve as an independent body to review requests from investigators and physicians seeking access to anonymized clinical trials data